RNA virus reverse genetics and vaccine design

Viruses

Volumn 6, Issue 7, 2014, Pages 2531-2550

  Stobart, Christopher C ^a,b   Moore, Martin L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Reverse genetics; RNA virus; Vaccines

Indexed keywords

VIRUS RNA; VIRUS VACCINE;

BACTERIAL ARTIFICIAL CHROMOSOME; CARCINOGENESIS; CORONAVIRUS; DENGUE VIRUS; DRUG DESIGN; GENE EXPRESSION; GENOMIC INSTABILITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS; MEASLES VIRUS; NONHUMAN; POLIOMYELITIS VIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE GENETICS; REVIEW; RHINOVIRUS; RNA VIRUS; VIRUS REPLICATION; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; FLAVIVIRIDAE; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; ORTHOMYXOVIRUS; PARAMYXOVIRIDAE; PROCEDURES; RNA VIRUS INFECTIONS; VIROLOGY; VIRUS GENOME;

ANIMALS; CORONAVIRIDAE; FLAVIVIRIDAE; GENETIC ENGINEERING; GENOME, VIRAL; HUMANS; ORTHOMYXOVIRIDAE; PARAMYXOVIRIDAE; REVERSE GENETICS; RNA VIRUS INFECTIONS; VIRAL VACCINES;

EID: 84903307226     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6072531     Document Type: Review

References (137)

1. Roush, S.W.; Murphy, T.V.; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the united states. JAMA 2007, 298, 2155-2163.
2. Racaniello, V.R.; Baltimore, D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981, 214, 916-919.
3. Almazan, F.; DeDiego, M.L.; Sola, I.; Zuniga, S.; Nieto-Torres, J.L.; Marquez-Jurado, S.; Andres, G.; Enjuanes, L. Engineering a replication-competent, propagation-defective middle east respiratory syndrome coronavirus as a vaccine candidate. mBio 2013, 4, e00650-e00613.
4. Almazan, F.; Gonzalez, J.M.; Penzes, Z.; Izeta, A.; Calvo, E.; Plana-Duran, J.; Enjuanes, L. Engineering the largest rna virus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA 2000, 97, 5516-5521.
5. Scobey, T.; Yount, B.L.; Sims, A.C.; Donaldson, E.F.; Agnihothram, S.S.; Menachery, V.D.; Graham, R.L.; Swanstrom, J.; Bove, P.F.; Kim, J.D.; et al. Reverse genetics with a full-length infectious cdna of the middle east respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 2013, 110, 16157-16162.
6. Shi, P.Y.; Tilgner, M.; Lo, M.K.; Kent, K.A.; Bernard, K.A. Infectious cdna clone of the epidemic west nile virus from new york city. J. Virol. 2002, 76, 5847-5856.
7. Thiel, V.; Herold, J.; Schelle, B.; Siddell, S.G. Infectious rna transcribed in vitro from a cdna copy of the human coronavirus genome cloned in vaccinia virus. J. Gen. Virol. 2001, 82, 1273-1281.
8. Yount, B.; Curtis, K.M.; Baric, R.S. Strategy for systematic assembly of large rna and DNA genomes: Transmissible gastroenteritis virus model. J. Virol. 2000, 74, 10600-10611.
9. Yount, B.; Curtis, K.M.; Fritz, E.A.; Hensley, L.E.; Jahrling, P.B.; Prentice, E.; Denison, M.R.; Geisbert, T.W.; Baric, R.S. Reverse genetics with a full-length infectious cdna of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 2003, 100, 12995-13000.
10. Yount, B.; Denison, M.R.; Weiss, S.R.; Baric, R.S. Systematic assembly of a full-length infectious cdna of mouse hepatitis virus strain a59. J. Virol. 2002, 76, 11065-11078.
11. Hoffmann, E.; Neumann, G.; Hobom, G.; Webster, R.G.; Kawaoka, Y. "Ambisense" approach for the generation of influenza a virus: Vrna and mrna synthesis from one template. Virology 2000, 267, 310-317.
12. Hoffmann, E.; Webster, R.G. Unidirectional rna polymerase i-polymerase ii transcription system for the generation of influenza a virus from eight plasmids. J. Gen. Virol. 2000, 81, 2843-2847.
13. Flatz, L.; Bergthaler, A.; de la Torre, J.C.; Pinschewer, D.D. Recovery of an arenavirus entirely from rna polymerase i/ii-driven cdna. Proc. Natl. Acad. Sci. USA 2006, 103, 4663-4668.
14. Yun, S.I.; Kim, S.Y.; Rice, C.M.; Lee, Y.M. Development and application of a reverse genetics system for japanese encephalitis virus. J. Virol. 2003, 77, 6450-6465.
15. Choi, Y.J.; Yun, S.I.; Kang, S.Y.; Lee, Y.M. Identification of 5' and 3' cis-acting elements of the porcine reproductive and respiratory syndrome virus: Acquisition of novel 5' au-rich sequences restored replication of a 5'-proximal 7-nucleotide deletion mutant. J. Virol. 2006, 80, 723-736.
16. St-Jean, J.R.; Desforges, M.; Almazan, F.; Jacomy, H.; Enjuanes, L.; Talbot, P.J. Recovery of a neurovirulent human coronavirus oc43 from an infectious cdna clone. J. Virol. 2006, 80, 3670-3674.
17. DeDiego, M.L.; Alvarez, E.; Almazan, F.; Rejas, M.T.; Lamirande, E.; Roberts, A.; Shieh, W.J.; Zaki, S.R.; Subbarao, K.; Enjuanes, L. A severe acute respiratory syndrome coronavirus that lacks the e gene is attenuated in vitro and in vivo. J. Virol. 2007, 81, 1701-1713.
18. Suzuki, R.; de Borba, L.; Duarte dos Santos, C.N.; Mason, P.W. Construction of an infectious cdna clone for a brazilian prototype strain of dengue virus type 1: Characterization of a temperature-sensitive mutation in ns1. Virology 2007, 362, 374-383.
19. Fan, Z.C.; Bird, R.C. An improved reverse genetics system for generation of bovine viral diarrhea virus as a bac cdna. J. Virol. Methods. 2008, 149, 309-315.
20. Rasmussen, T.B.; Reimann, I.; Uttenthal, A.; Leifer, I.; Depner, K.; Schirrmeier, H.; Beer, M. Generation of recombinant pestiviruses using a full-genome amplification strategy. Vet. Microbiol. 2010, 142, 13-17.
21. Hotard, A.L.; Shaikh, F.Y.; Lee, S.; Yan, D.; Teng, M.N.; Plemper, R.K.; Crowe, J.E., Jr.; Moore, M.L. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012, 434, 129-136.
22. Balint, A.; Farsang, A.; Zadori, Z.; Hornyak, A.; Dencso, L.; Almazan, F.; Enjuanes, L.; Belak, S. Molecular characterization of feline infectious peritonitis virus strain df-2 and studies of the role of orf3abc in viral cell tropism. J. Virol. 2012, 86, 6258-6267.
23. Usme-Ciro, J.A.; Lopera, J.A.; Enjuanes, L.; Almazan, F.; Gallego-Gomez, J.C. Development of a novel DNA-launched dengue virus type 2 infectious clone assembled in a bacterial artificial chromosome. Virus Res. 2014, 180, 12-22.
24. Kandolf, R.; Hofschneider, P.H. Molecular cloning of the genome of a cardiotropic coxsackie b3 virus: Full-length reverse-transcribed recombinant cdna generates infectious virus in mammalian cells. Proc. Natl. Acad. Sci. USA 1985, 82, 4818-4822.
25. Mizutani, S.; Colonno, R.J. In vitro synthesis of an infectious rna from cdna clones of human rhinovirus type 14. J. Virol. 1985, 56, 628-632.
26. Cohen, J.I.; Ticehurst, J.R.; Feinstone, S.M.; Rosenblum, B.; Purcell, R.H. Hepatitis a virus cdna and its rna transcripts are infectious in cell culture. J. Virol. 1987, 61, 3035-3039.
27. Roos, R.P.; Stein, S.; Routbort, M.; Senkowski, A.; Bodwell, T.; Wollmann, R. Theiler's murine encephalomyelitis virus neutralization escape mutants have a change in disease phenotype. J. Virol. 1989, 63, 4469-4473.
28. Zibert, A.; Maass, G.; Strebel, K.; Falk, M.M.; Beck, E. Infectious foot-and-mouth disease virus derived from a cloned full-length cdna. J. Virol. 1990, 64, 2467-2473.
29. Inoue, T.; Yamaguchi, S.; Saeki, T.; Sekiguchi, K. Production of infectious swine vesicular disease virus from cloned cdna in mammalian cells. J. Gen. Virol. 1990, 71, 1835-1838.
30. Blackburn, R.V.; Racaniello, V.R.; Righthand, V.F. Construction of an infectious cdna clone of echovirus 6. Virus Res. 1992, 22, 71-78.
31. Zimmermann, H.; Eggers, H.J.; Zimmermann, A.; Kraus, W.; Nelsen-Salz, B. Complete nucleotide sequence and biological properties of an infectious clone of prototype echovirus 9. Virus Res. 1995, 39, 311-319.
32. Palmenberg, A.C.; Spiro, D.; Kuzmickas, R.; Wang, S.; Djikeng, A.; Rathe, J.A.; Fraser-Liggett, C.M.; Liggett, S.B. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009, 324, 55-59.
33. Waman, V.P.; Kolekar, P.S.; Kale, M.M.; Kulkarni-Kale, U. Population structure and evolution of rhinoviruses. PLoS One 2014, 9, e88981.
34. Glanville, N.; McLean, G.R.; Guy, B.; Lecouturier, V.; Berry, C.; Girerd, Y.; Gregoire, C.; Walton, R.P.; Pearson, R.M.; Kebadze, T.; et al. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. PLoS Pathog. 2013, 9, e1003669.
35. Rossmann, M.G.; Arnold, E.; Erickson, J.W.; Frankenberger, E.A.; Griffith, J.P.; Hecht, H.J.; Johnson, J.E.; Kamer, G.; Luo, M.; Mosser, A.G.; et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985, 317, 145-153.
36. Edlmayr, J.; Niespodziana, K.; Popow-Kraupp, T.; Krzyzanek, V.; Focke-Tejkl, M.; Blaas, D.; Grote, M.; Valenta, R. Antibodies induced with recombinant vp1 from human rhinovirus exhibit cross-neutralisation. Euro. Respir. J. 2011, 37, 44-52.
37. Bartlett, N.W.; Walton, R.P.; Edwards, M.R.; Aniscenko, J.; Caramori, G.; Zhu, J.; Glanville, N.; Choy, K.J.; Jourdan, P.; Burnet, J.; et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med. 2008, 14, 199-204.
38. Dobrikova, E.Y.; Goetz, C.; Walters, R.W.; Lawson, S.K.; Peggins, J.O.; Muszynski, K.; Ruppel, S.; Poole, K.; Giardina, S.L.; Vela, E.M.; et al. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:Rhinovirus chimera after intrathalamic inoculation in macaca fascicularis. J. Virol. 2012, 86, 2750-2759.
39. Jahan, N.; Wimmer, E.; Mueller, S. Polypyrimidine tract binding protein-1 (ptb1) is a determinant of the tissue and host tropism of a human rhinovirus/poliovirus chimera pv1(ripo). PLoS One 2013, 8, e60791.
40. Perlman, S.; Netland, J. Coronaviruses post-sars: Update on replication and pathogenesis. Nat. Rev. Microbiol. 2009, 7, 439-450.
41. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in saudi arabia. New Engl. J. Med. 2012, 367, 1814-1820.
42. Donaldson, E.F.; Yount, B.; Sims, A.C.; Burkett, S.; Pickles, R.J.; Baric, R.S. Systematic assembly of a full-length infectious clone of human coronavirus nl63. J. Virol. 2008, 82, 11948-11957.
43. Becker, M.M.; Graham, R.L.; Donaldson, E.F.; Rockx, B.; Sims, A.C.; Sheahan, T.; Pickles, R.J.; Corti, D.; Johnston, R.E.; Baric, R.S.; et al. Synthetic recombinant bat sars-like coronavirus is infectious in cultured cells and in mice. Proc. Natl. Acad. Sci. USA 2008, 105, 19944-19949.
44. Eckerle, L.D.; Lu, X.; Sperry, S.M.; Choi, L.; Denison, M.R. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J. Virol. 2007, 81, 12135-12144.
45. Smith, E.C.; Blanc, H.; Vignuzzi, M.; Denison, M.R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathog. 2013, 9, e1003565.
46. Denison, M.R.; Graham, R.L.; Donaldson, E.F.; Eckerle, L.D.; Baric, R.S. Coronaviruses: An rna proofreading machine regulates replication fidelity and diversity. RNA Biol. 2011, 8, 270-279.
47. Eckerle, L.D.; Becker, M.M.; Halpin, R.A.; Li, K.; Venter, E.; Lu, X.; Scherbakova, S.; Graham, R.L.; Baric, R.S.; Stockwell, T.B.; et al. Infidelity of sars-cov nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 2010, 6, e1000896.
48. Graham, R.L.; Becker, M.M.; Eckerle, L.D.; Bolles, M.; Denison, M.R.; Baric, R.S. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat. Med. 2012, 18, 1820-1826.
49. Hotez, P.J.; Bottazzi, M.E.; Tseng, C.T.; Zhan, B.; Lustigman, S.; Du, L.; Jiang, S. Calling for rapid development of a safe and effective mers vaccine. Microbes Infect. 2014, doi:10.1016/j.micinf.2014.05.002.
50. Ying, T.; Du, L.; Ju, T.W.; Prabakaran, P.; Lau, C.C.; Lu, L.; Liu, Q.; Wang, L.; Feng, Y.; Wang, Y.; et al. Exceptionally potent neutralization of mers-cov by human monoclonal antibodies. J. Virol. 2014.
51. Tang, X.C.; Agnihothram, S.S.; Jiao, Y.; Stanhope, J.; Graham, R.L.; Peterson, E.C.; Avnir, Y.; Tallarico, A.S.; Sheehan, J.; Zhu, Q.; et al. Identification of human neutralizing antibodies against mers-cov and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. USA 2014, 111, E2018-E2026.
52. Ma, C.; Li, Y.; Wang, L.; Zhao, G.; Tao, X.; Tseng, C.T.; Zhou, Y.; Du, L.; Jiang, S. Intranasal vaccination with recombinant receptor-binding domain of mers-cov spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal mers vaccines. Vaccine 2014, 32, 2100-2108.
53. Ishikawa, T.; Yamanaka, A.; Konishi, E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 2014, 32, 1326-1337.
54. Reed, W.; Carroll, J. The prevention of yellow fever. Public Health Pap. Rep. 1901, 27, 113-129.
55. Reed, W.; Carroll, J.; Agramonte, A. The etiology of yellow fever: An additional note. 1901. Mil. Med. 2001, 166, 44-53.
56. Reed, W. Recent researches concerning the etiology, propagation, and prevention of yellow fever, by the united states army commission. J. Hyg. 1902, 2, 101-119.
57. Rice, C.M.; Grakoui, A.; Galler, R.; Chambers, T.J. Transcription of infectious yellow fever rna from full-length cdna templates produced by in vitro ligation. The New biologist 1989, 1, 285-296.
58. Bredenbeek, P.J.; Kooi, E.A.; Lindenbach, B.; Huijkman, N.; Rice, C.M.; Spaan, W.J. A stable full-length yellow fever virus cdna clone and the role of conserved rna elements in flavivirus replication. J. Gen. Virol. 2003, 84, 1261-1268.
59. Kapoor, M.; Zhang, L.; Mohan, P.M.; Padmanabhan, R. Synthesis and characterization of an infectious dengue virus type-2 rna genome (new guinea c strain). Gene 1995, 162, 175-180.
60. Kinney, R.M.; Butrapet, S.; Chang, G.J.; Tsuchiya, K.R.; Roehrig, J.T.; Bhamarapravati, N.; Gubler, D.J. Construction of infectious cdna clones for dengue 2 virus: Strain 16681 and its attenuated vaccine derivative, strain pdk-53. Virology 1997, 230, 300-308.
61. Polo, S.; Ketner, G.; Levis, R.; Falgout, B. Infectious rna transcripts from full-length dengue virus type 2 cdna clones made in yeast. J. Virol. 1997, 71, 5366-5374.
62. Puri, B.; Polo, S.; Hayes, C.G.; Falgout, B. Construction of a full length infectious clone for dengue-1 virus western pacific,74 strain. Virus Genes 2000, 20, 57-63.
63. Blaney, J.E., Jr.; Hanson, C.T.; Firestone, C.Y.; Hanley, K.A.; Murphy, B.R.; Whitehead, S.S. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am. J. Trop. Med. Hyg. 2004, 71, 811-821.
64. Blaney, J.E., Jr.; Hanson, C.T.; Hanley, K.A.; Murphy, B.R.; Whitehead, S.S. Vaccine candidates derived from a novel infectious cdna clone of an american genotype dengue virus type 2. BMC Infect. Dis. 2004, 4, 39.
65. Chen, W.; Kawano, H.; Men, R.; Clark, D.; Lai, C.J. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J. Virol. 1995, 69, 5186-5190.
66. Lai, C.J.; Zhao, B.T.; Hori, H.; Bray, M. Infectious rna transcribed from stably cloned full-length cdna of dengue type 4 virus. Proc. Natl. Acad. Sci. USA 1991, 88, 5139-5143.
67. Sumiyoshi, H.; Hoke, C.H.; Trent, D.W. Infectious japanese encephalitis virus rna can be synthesized from in vitro-ligated cdna templates. J. Virol. 1992, 66, 5425-5431.
68. Khromykh, A.A.; Westaway, E.G. Completion of kunjin virus rna sequence and recovery of an infectious rna transcribed from stably cloned full-length cdna. J. Virol. 1994, 68, 4580-4588.
69. Gritsun, T.S.; Gould, E.A. Infectious transcripts of tick-borne encephalitis virus, generated in days by rt-pcr. Virology 1995, 214, 611-618.
70. Gritsun, T.S.; Gould, E.A. Development and analysis of a tick-borne encephalitis virus infectious clone using a novel and rapid strategy. J. Virol. Methods. 1998, 76, 109-120.
71. Mandl, C.W.; Ecker, M.; Holzmann, H.; Kunz, C.; Heinz, F.X. Infectious cdna clones of tick-borne encephalitis virus european subtype prototypic strain neudoerfl and high virulence strain hypr. J. Gen. Virol. 1997, 78, 1049-1057.
72. Hurrelbrink, R.J.; Nestorowicz, A.; McMinn, P.C. Characterization of infectious murray valley encephalitis virus derived from a stably cloned genome-length cdna. J. Gen. Virol. 1999, 80, 3115-3125.
73. Campbell, M.S.; Pletnev, A.G. Infectious cdna clones of langat tick-borne flavivirus that differ from their parent in peripheral neurovirulence. Virology 2000, 269, 225-237.
74. Yamshchikov, V.F.; Wengler, G.; Perelygin, A.A.; Brinton, M.A.; Compans, R.W. An infectious clone of the west nile flavivirus. Virology 2001, 281, 294-304.
75. Yoshii, K.; Igarashi, M.; Ito, K.; Kariwa, H.; Holbrook, M.R.; Takashima, I. Construction of an infectious cdna clone for omsk hemorrhagic fever virus, and characterization of mutations in ns2a and ns5. Virus Res. 2011, 155, 61-68.
76. Theiler, M.; Smith, H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937, 65, 787-800.
77. Bonaldo, M.C.; Sequeira, P.C.; Galler, R. The yellow fever 17d virus as a platform for new live attenuated vaccines. Hum. Vaccin. Immunother. 2014, 10, 1256-1265.
78. Lefeuvre, A.; Marianneau, P.; Deubel, V. Current assessment of yellow fever and yellow fever vaccine. Curr. Infect. Dis. Rep. 2004, 6, 96-104.
79. Poland, J.D.; Calisher, C.H.; Monath, T.P.; Downs, W.G.; Murphy, K. Persistence of neutralizing antibody 30-35 years after immunization with 17d yellow fever vaccine. Bull. World Health Organ. 1981, 59, 895-900.
80. Webster, L.T. Japanese b encephalitis virus: Its differentiation from st. Louis encephalitis virus and relationship to louping-ill virus. Science 1937, 86, 402-403.
81. Normile, D. Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science 2013, 342, 415.
82. Halstead, S.B. Immune enhancement of viral infection. Prog. Allergy 1982, 31, 301-364.
83. Guirakhoo, F.; Arroyo, J.; Pugachev, K.V.; Miller, C.; Zhang, Z.X.; Weltzin, R.; Georgakopoulos, K.; Catalan, J.; Ocran, S.; Soike, K.; et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 2001, 75, 7290-7304.
84. Caufour, P.S.; Motta, M.C.; Yamamura, A.M.; Vazquez, S.; Ferreira, II; Jabor, A.V.; Bonaldo, M.C.; Freire, M.S.; Galler, R. Construction, characterization and immunogenicity of recombinant yellow fever 17d-dengue type 2 viruses. Virus Res. 2001, 79, 1-14.
85. Guy, B.; Guirakhoo, F.; Barban, V.; Higgs, S.; Monath, T.P.; Lang, J. Preclinical and clinical development of yfv 17d-based chimeric vaccines against dengue, west nile and japanese encephalitis viruses. Vaccine 2010, 28, 632-649.
86. Arroyo, J.; Miller, C.; Catalan, J.; Myers, G.A.; Ratterree, M.S.; Trent, D.W.; Monath, T.P. Chimerivax-west nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 2004, 78, 12497-12507.
87. Schnell, M.J.; Mebatsion, T.; Conzelmann, K.K. Infectious rabies viruses from cloned cdna. EMBO J. 1994, 13, 4195-4203.
88. Conzelmann, K.K.; Schnell, M. Rescue of synthetic genomic rna analogs of rabies virus by plasmid-encoded proteins. J. Virol. 1994, 68, 713-719.
89. Radecke, F.; Spielhofer, P.; Schneider, H.; Kaelin, K.; Huber, M.; Dotsch, C.; Christiansen, G.; Billeter, M.A. Rescue of measles viruses from cloned DNA. EMBO J. 1995, 14, 5773-5784.
90. Clarke, D.K.; Sidhu, M.S.; Johnson, J.E.; Udem, S.A. Rescue of mumps virus from cdna. J. Virol. 2000, 74, 4831-4838.
91. Marsh, G.A.; Virtue, E.R.; Smith, I.; Todd, S.; Arkinstall, R.; Frazer, L.; Monaghan, P.; Smith, G.A.; Broder, C.C.; Middleton, D.; et al. Recombinant hendra viruses expressing a reporter gene retain pathogenicity in ferrets. Virol. J. 2013, 10, 95.
92. Yoneda, M.; Guillaume, V.; Ikeda, F.; Sakuma, Y.; Sato, H.; Wild, T.F.; Kai, C. Establishment of a nipah virus rescue system. Proc. Natl. Acad. Sci. USA 2006, 103, 16508-16513.
93. Collins, P.L.; Murphy, B.R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thorac. Soc. 2005, 2, 166-173.
94. Katz, S.L.; John, F. Enders and measles virus vaccine-A reminiscence. Curr. Top. Microbiol. Immunol. 2009, 329, 3-11.
95. Buynak, E.B.; Hilleman, M.R. Live attenuated mumps virus vaccine. 1. Vaccine development. Exp. Biol. Med. 1966, 123, 768-775.
96. Stokes, J., Jr.; Weibel, R.E.; Villarejos, V.M.; Arguedas, J.A.; Buynak, E.B.; Hilleman, M.R. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. JAMA 1971, 218, 57-61.
97. Blount, R.E., Jr.; Morris, J.A.; Savage, R.E. Recovery of cytopathogenic agent from chimpanzees with coryza. Exp. Biol. Med. 1956, 92, 544-549.
98. Hall, C.B.; Weinberg, G.A.; Iwane, M.K.; Blumkin, A.K.; Edwards, K.M.; Staat, M.A.; Auinger, P.; Griffin, M.R.; Poehling, K.A.; Erdman, D.; et al. The burden of respiratory syncytial virus infection in young children. New Engl. J. Med. 2009, 360, 588-598.
99. Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O'Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N.; et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010, 375, 1545-1555.
100. Glezen, W.P.; Taber, L.H.; Frank, A.L.; Kasel, J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986, 140, 543-546.
101. Subramanian, K.N.; Weisman, L.E.; Rhodes, T.; Ariagno, R.; Sanchez, P.J.; Steichen, J.; Givner, L.B.; Jennings, T.L.; Top, F.H., Jr.; Carlin, D.; et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Medi-493 study group. J. Pediatr. Infect. Dis. 1998, 17, 110-115.
102. Abarca, K.; Jung, E.; Fernandez, P.; Zhao, L.; Harris, B.; Connor, E.M.; Losonsky, G.A.; Motavizumab Study, G. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. J. Pediatr. Infect. Dis. 2009, 28, 267-272.
103. Kamal-Bahl, S.; Doshi, J.; Campbell, J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: A systematic review. Arch. Pediatr. Adolesc. Med. 2002, 156, 1034-1041.
104. Kim, H.W.; Leikin, S.L.; Arrobio, J.; Brandt, C.D.; Chanock, R.M.; Parrott, R.H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 1976, 10, 75-78.
105. Collins, P.L.; Melero, J.A. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res. 2011, 162, 80-99.
106. Karron, R.A.; Wright, P.F.; Belshe, R.B.; Thumar, B.; Casey, R.; Newman, F.; Polack, F.P.; Randolph, V.B.; Deatly, A.; Hackell, J.; et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 2005, 191, 1093-1104.
107. Schickli, J.H.; Kaur, J.; Tang, R.S. Nonclinical phenotypic and genotypic analyses of a phase 1 pediatric respiratory syncytial virus vaccine candidate medi-559 (ra2cp248/404/1030deltash) at permissive and non-permissive temperatures. Virus Res. 2012, 169, 38-47.
108. Luongo, C.; Winter, C.C.; Collins, P.L.; Buchholz, U.J. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J. Virol. 2012, 86, 10792-10804.
109. Graham, B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 2011, 239, 149-166.
110. Engelhardt, O.G. Many ways to make an influenza virus-Review of influenza virus reverse genetics methods. Influenza Other Respir. Viruses 2013, 7, 249-256.
111. Enami, M.; Luytjes, W.; Krystal, M.; Palese, P. Introduction of site-specific mutations into the genome of influenza virus. Proc. Natl. Acad. Sci. USA 1990, 87, 3802-3805.
112. Luytjes, W.; Krystal, M.; Enami, M.; Parvin, J.D.; Palese, P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989, 59, 1107-1113.
113. Fodor, E.; Devenish, L.; Engelhardt, O.G.; Palese, P.; Brownlee, G.G.; Garcia-Sastre, A. Rescue of influenza a virus from recombinant DNA. J. Virol. 1999, 73, 9679-9682.
114. Neumann, G.; Kawaoka, Y. Generation of influenza a virus from cloned cdnas--historical perspective and outlook for the new millenium. Rev. Med. Virol. 2002, 12, 13-30.
115. Koudstaal, W.; Hartgroves, L.; Havenga, M.; Legastelois, I.; Ophorst, C.; Sieuwerts, M.; Zuijdgeest, D.; Vogels, R.; Custers, J.; de Boer-Luijtze, E.; et al. Suitability of per. C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 2009, 27, 2588-2593.
116. de Wit, E.; Spronken, M.I.; Vervaet, G.; Rimmelzwaan, G.F.; Osterhaus, A.D.; Fouchier, R.A. A reverse-genetics system for influenza a virus using t7 rna polymerase. J. Gen. Virol. 2007, 88, 1281-1287.
117. Crescenzo-Chaigne, B.; van der Werf, S. Rescue of influenza c virus from recombinant DNA. J. Virol. 2007, 81, 11282-11289.
118. Muraki, Y.; Murata, T.; Takashita, E.; Matsuzaki, Y.; Sugawara, K.; Hongo, S. A mutation on influenza c virus m1 protein affects virion morphology by altering the membrane affinity of the protein. J. Virol. 2007, 81, 8766-8773.
119. Massin, P.; Rodrigues, P.; Marasescu, M.; van der Werf, S.; Naffakh, N. Cloning of the chicken rna polymerase i promoter and use for reverse genetics of influenza a viruses in avian cells. J. Virol. 2005, 79, 13811-13816.
120. Murakami, S.; Horimoto, T.; Yamada, S.; Kakugawa, S.; Goto, H.; Kawaoka, Y. Establishment of canine rna polymerase i-driven reverse genetics for influenza a virus: Its application for h5n1 vaccine production. J. Virol. 2008, 82, 1605-1609.
121. Neumann, G.; Fujii, K.; Kino, Y.; Kawaoka, Y. An improved reverse genetics system for influenza a virus generation and its implications for vaccine production. Proc. Natl. Acad. Sci. USA 2005, 102, 16825-16829.
122. Vinnemeier, C.D.; Fischer-Herr, J.; Meyer, S.; Liebig, K.; Theess, W.; Burchard, G.D.; Cramer, J.P. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (optaflu): An open label, uncontrolled study. Hum. Vaccin. Immunother. 2013, 10, 441-448.
123. Doroshenko, A.; Halperin, S.A. Trivalent mdck cell culture-derived influenza vaccine optaflu (novartis vaccines). Expert Rev. Vaccin. 2009, 8, 679-688.
124. Bright, R.A.; Carter, D.M.; Daniluk, S.; Toapanta, F.R.; Ahmad, A.; Gavrilov, V.; Massare, M.; Pushko, P.; Mytle, N.; Rowe, T.; et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25, 3871-3878.
125. Pushko, P.; Tumpey, T.M.; Van Hoeven, N.; Belser, J.A.; Robinson, R.; Nathan, M.; Smith, G.; Wright, D.C.; Bright, R.A. Evaluation of influenza virus-like particles and novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25, 4283-4290.
126. Pushko, P.; Tumpey, T.M.; Bu, F.; Knell, J.; Robinson, R.; Smith, G. Influenza virus-like particles comprised of the ha, na, and m1 proteins of h9n2 influenza virus induce protective immune responses in balb/c mice. Vaccine 2005, 23, 5751-5759.
127. Galarza, J.M.; Latham, T.; Cupo, A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005, 18, 365-372.
128. Quan, F.S.; Huang, C.; Compans, R.W.; Kang, S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81, 3514-3524.
129. Treanor, J.J.; Schiff, G.M.; Hayden, F.G.; Brady, R.C.; Hay, C.M.; Meyer, A.L.; Holden-Wiltse, J.; Liang, H.; Gilbert, A.; Cox, M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. JAMA 2007, 297, 1577-1582.
130. Traynor, K. First recombinant flu vaccine approved. AJHP 2013, 70, 382.
131. Yang, L.P. Recombinant trivalent influenza vaccine (flublok(®): A review of its use in the prevention of seasonal influenza in adults. Drugs 2013, 73, 1357-1366.
132. Dormitzer, P.R.; Suphaphiphat, P.; Gibson, D.G.; Wentworth, D.E.; Stockwell, T.B.; Algire, M.A.; Alperovich, N.; Barro, M.; Brown, D.M.; Craig, S.; et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci. Transl. Med. 2013, 5, 185ra168.
133. Burns, C.C.; Shaw, J.; Campagnoli, R.; Jorba, J.; Vincent, A.; Quay, J.; Kew, O. Modulation of poliovirus replicative fitness in hela cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 2006, 80, 3259-3272.
134. Mueller, S.; Papamichail, D.; Coleman, J.R.; Skiena, S.; Wimmer, E. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 2006, 80, 9687-9696.
135. Dormitzer, P.R.; Grandi, G.; Rappuoli, R. Structural vaccinology starts to deliver. Nat. Rev. Microbiol. 2012, 10, 807-813.
136. Correia, B.E.; Bates, J.T.; Loomis, R.J.; Baneyx, G.; Carrico, C.; Jardine, J.G.; Rupert, P.; Correnti, C.; Kalyuzhniy, O.; Vittal, V.; et al. Proof of principle for epitope-focused vaccine design. Nature 2014, 507, 201-206.
137. McLellan, J.S.; Chen, M.; Joyce, M.G.; Sastry, M.; Stewart-Jones, G.B.; Yang, Y.; Zhang, B.; Chen, L.; Srivatsan, S.; Zheng, A.; et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342, 592-598.